Free Trial
LON:FARN

Faron Pharmaceuticals Oy (FARN) Share Price, News & Analysis

Faron Pharmaceuticals Oy logo
GBX 241.67 +13.67 (+5.99%)
As of 06:19 AM Eastern

About Faron Pharmaceuticals Oy Stock (LON:FARN)

Key Stats

Today's Range
240
245
50-Day Range
185
250
52-Week Range
85
265
Volume
14,085 shs
Average Volume
45,030 shs
Market Capitalization
£324.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. Currently in phase I/II clinical development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, Clevegen has potential as a single-agent therapy or in combination with other standard treatments including immune checkpoint molecules. Traumakine, the Company's pipeline candidate to prevent vascular leakage and organ failures is currently being tested in several Phase III studies around the world against COVID-19. Traumakine is intravenous IFN beta-1a, which is a strong anti-viral and anti-inflammatory agent. Faron is based in Turku, Finland. Further information is available at www.faron.com

Receive FARN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Faron Pharmaceuticals Oy and its competitors with MarketBeat's FREE daily newsletter.

FARN Stock News Headlines

Trump Exec Order 14179 is wealth “gift” to good Americans?
Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve suffered financial hardship…Our President may have solved everything.
Faron Pharmaceuticals Ltd: Grant of Options
See More Headlines

FARN Stock Analysis - Frequently Asked Questions

Faron Pharmaceuticals Oy's stock was trading at GBX 207 at the beginning of the year. Since then, FARN stock has increased by 20.8% and is now trading at GBX 250.
View the best growth stocks for 2025 here
.

Shares of FARN stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

Based on aggregate information from My MarketBeat watchlists, some other companies that Faron Pharmaceuticals Oy investors own include Horizon Discovery Group plc (HZD.L) (HZD), Greencore Group (GNC), Premier African Minerals (PREM), Babcock International Group (BAB), Barclays (BARC), B&M European Value Retail (BME) and Coats Group (COA).

Industry, Sector and Symbol

Stock Exchange
LON
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
LON:FARN
CIK
N/A
Fax
N/A
Employees
34
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-£60.23 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Cash Flow
GBX 11.40 per share
Price / Cash Flow
20.00
Book Value
GBX 1,957.36 per share
Price / Book
0.12

Miscellaneous

Free Float
N/A
Market Cap
£306.09 million
Optionable
Not Optionable
Beta
0.36
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (LON:FARN) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners